Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report 2026

Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Overview

• Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs market size has reached to $15.5 billion in 2025 • Expected to grow to $32.87 billion in 2030 at a compound annual growth rate (CAGR) of 16.2% • Growth Driver: Rising Prevalence Of Obesity Fueling The Growth Of The Market Due To Increasing Demand For Effective Weight Management Solutions • Market Trend: Innovative GLP-1Based Therapies Driving Advances In Obesity Treatment • North America was the largest region in 2025.

What Is Covered Under Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?

Glucagon-like peptide (GLP)-1 agonists are medications that replicate the action of the GLP-1 hormone to help control blood sugar and reduce appetite. They boost insulin release, delay stomach emptying, and increase feelings of fullness. Initially designed for type 2 diabetes, they are now commonly used for weight management in overweight and obese patients. The main drugs involved in glucagon-like peptide (GLP)-1 agonists weight loss drugs market are semaglutide, liraglutide, tirzepatide, and other drugs. Semaglutide, marketed as wegovy, is an injectable prescription medication designed to aid weight loss in adults with obesity or overweight conditions accompanied by weight-related health issues. The different routes of administration include parenteral and oral and are distributed through hospital pharmacies, retail pharmacies, and other pharmacies.

What Is The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Growth Forecast?

The glucagon-like peptide (glp)-1 agonists weight loss drugs market size is expected to see rapid growth in the next few years. It will grow to $32.87 billion in 2030 at a compound annual growth rate (CAGR) of 16.2%. The growth in the forecast period can be attributed to approval of new glp-1 drugs, expansion of obesity clinics, increased insurance coverage, long-term weight management focus, rising global obesity rates. Major trends in the forecast period include rising demand for pharmacological weight management, increased use of injectable weight loss drugs, growing adoption of glp-1 therapies beyond diabetes, expansion of obesity treatment programs, improved patient adherence to long-term therapy.

What Is The Driver Of The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?

The rising prevalence of obesity is expected to propel the growth of the glucagon-like peptide (GLP)-1 agonist weight loss drugs market going forward. Obesity refers to a medical condition characterized by excessive body fat accumulation that presents a risk to health. Obesity rates are growing due to unhealthy eating habits where people consume more fast food and sugary drinks, lacking proper nutrition and balance. As the number of individuals affected by obesity and its related complications continues to rise, the demand for effective treatment options is increasing, thereby driving the use of glucagon-like peptide (GLP-1) agonist weight loss drugs for their proven ability to support weight loss and enhance metabolic health. For instance, in May 2025, according to the Office for Health Improvement and Disparities, a UK-based government body, from 2023 to 2024, an estimated 64.5% of adults aged 18 and over in England were overweight or living with obesity, up from 64.0% in 2022 to 2023. Therefore, the rising prevalence of obesity is driving the growth of glucagon-like peptide (GLP)-1 agonist weight loss drugs market.

Key Players In The Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market

Major companies operating in the glucagon-like peptide (glp)-1 agonists weight loss drugs market are Novo Nordisk A/S, Eli Lilly and Company, Pfizer Inc., Merck & Co Inc, Boehringer Ingelheim, Hanmi Pharmaceutical, Jiangsu Hengrui Medicine Co Ltd, Zealand Pharma A/S, I-Mab Biopharma Shanghai Co Ltd, Altimmune Inc, BioAge Labs, Innovent Biologics Inc, Viking Therapeutics Inc, Structure Therapeutics Inc, Regor Therapeutics Inc, TheracosBio LLC, Oramed Pharmaceuticals, Amgen Inc, Roche Holding AG, Teva Pharmaceutical Industries Ltd

Global Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Trends and Insights

Major companies operating in the glucagon-like peptide (GLP)-1 agonist weight loss drugs market are developing innovative obesity treatment solutions to enhance efficacy and improve patient outcomes. Obesity treatment solutions refer to therapies that mimic the GLP-1 hormone to regulate appetite, enhance satiety, and promote weight loss. These drugs help manage obesity by improving metabolic function and supporting long-term weight control. For instance, in November 2023, Eli Lilly and Company, a US-based pharmaceutical company, received US Food and Drug Administration approval for Zepbound, a medication for chronic weight management in adults with obesity or overweight who have related health conditions such as type 2 diabetes or sleep apnea. The drug works by activating GIP and GLP-1 hormone receptors to suppress appetite and enhance metabolic function.

What Are Latest Mergers And Acquisitions In The Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?

In December 2023, F. Hoffmann-La Roche AG, a Switzerland-based healthcare company, acquired Carmot Therapeutics for $2.7 billion. With this acquisition, Roche gains access to Carmot's pipeline of incretin-based therapies for obesity and diabetes, including dual GLP-1/GIP receptor agonists CT-388 and CT-868 and GLP-1 receptor agonist CT-996. Carmot Therapeutics Inc. is a US-based biotechnology company that focuses on developing disease-modifying therapies for metabolic diseases, such as obesity and diabetes.

What Defines the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market?

The glucagon-like peptide (GLP)-1 agonists weight loss drugs market consists of sales of products such as dulaglutide (trulicity), exenatide (byetta, bydureon), and lixisenatide (adlyxin). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Glucagon-Like Peptide (GLP)-1 Agonists Weight Loss Drugs Market Report 2026?

The glucagon-like peptide (glp)-1 agonists weight loss drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the glucagon-like peptide (glp)-1 agonists weight loss drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.